Traditional biomarkers for immunotherapy, such as tumor mutation burden and PD-L1 expression in lung tumors, have been established; however, the prognostic value and applicability of PD-L1 in HNSCC remain unproven. The gene discussed is CD274; the disease is neoplasm.